List of Excipients in Branded Drug TAZICEF

« Back to Dashboard

Generic Drugs Containing TAZICEF

Company	Ingredient	NDC	Excipient
Hospira Inc	ceftazidime	0409-5084	SODIUM CARBONATE
Hospira Inc	ceftazidime	0409-5086	SODIUM CARBONATE
Hospira Inc	ceftazidime	0409-5092	SODIUM CARBONATE

What are the Most Frequently-Used Excipients in TAZICEF?

# Of NDCs	Excipient
3	SODIUM CARBONATE

Tazicef Excipient Strategy and Commercial Opportunities for Ceftazidime Injection

Last updated: October 7, 2026

Tazicef is an older ceftazidime injectable product whose commercial value is driven by hospital supply reliability, reconstitution convenience, stability, and procurement economics rather than compound exclusivity. Its core excipient system is limited: ceftazidime is supplied as a sterile powder with sodium carbonate used to support solubility and formulation pH. The strongest opportunities are ready-to-use presentations, extended in-use stability, simplified preparation, and differentiated hospital packaging.

What is Tazicef and which drug does it contain?

Tazicef contains ceftazidime, a third-generation cephalosporin administered by intravenous or intramuscular injection. Ceftazidime has activity against several Gram-negative organisms, including Pseudomonas aeruginosa, and is used for serious bacterial infections under hospital or specialist supervision.

The product is supplied as a sterile ceftazidime powder for reconstitution. The formulation does not depend on a complex excipient platform. Sodium carbonate is used as a buffering and alkalizing agent to support ceftazidime solubility and product stability. The vials are generally preservative-free and intended for single-dose use.

Attribute	Tazicef
Active ingredient	Ceftazidime
Drug class	Third-generation cephalosporin
Main dosage form	Sterile powder for injection
Administration	Intravenous or intramuscular
Key formulation excipient	Sodium carbonate
Preservative profile	Typically preservative-free
Primary setting	Hospitals, outpatient parenteral antibiotic therapy, emergency care
Main commercial competitors	Generic ceftazidime injection, Fortaz legacy products, hospital-premix products
Core commercial issue	Supply, preparation time, stability, and price

FDA labeling identifies ceftazidime for injection as a powder requiring reconstitution before administration. The label also provides compatibility information for common diluents, including sterile water for injection, 0.9% sodium chloride, and dextrose-containing solutions, subject to product-specific concentration and storage conditions (U.S. Food and Drug Administration [FDA], n.d.-a).

What excipients are used in Tazicef?

The principal excipient is sodium carbonate. The formulation strategy is intentionally narrow because ceftazidime is supplied as a sterile dry powder rather than as a liquid injection.

Sodium carbonate

Sodium carbonate has several formulation functions:

• Raises pH to improve ceftazidime solubility.
• Supports formation of a stable injectable solution after reconstitution.
• Controls the chemical environment during manufacture and storage.
• Avoids reliance on surfactants, preservatives, or complex cosolvent systems.

The use of sodium carbonate also affects the reconstituted solution's pH and compatibility profile. A reformulator cannot treat it as an inert filler. Changes in carbonate level can influence solubility, degradation, osmolality, injection tolerability, and compatibility with infusion solutions.

Water for injection

Water for injection is used by the hospital or pharmacy to reconstitute the vial. It is generally a diluent rather than a component of the dry powder. The final solution may then be further diluted for intravenous infusion.

Sodium chloride and dextrose diluents

Commercial opportunity exists in pairing ceftazidime with a ready-to-use diluent, including 0.9% sodium chloride or dextrose solutions. This changes the product from a conventional vial into a premixed infusion presentation. Such products require separate evaluation of container compatibility, pH drift, degradation, particulate formation, sterility, and labeled storage conditions.

Preservatives and antimicrobial agents

A preservative is generally undesirable for an injectable cephalosporin intended for intravenous use. Preservatives can create compatibility and tolerability issues and may limit use in neonates, pediatrics, and patients requiring repeated dosing. A preservative-free product is commercially preferable for hospital use, provided the packaging and in-use instructions control contamination risk.

What formulation patents protect Tazicef?

Tazicef's commercial product is not protected by a meaningful modern compound patent estate. Ceftazidime was introduced decades ago, and the original compound and basic injectable formulation rights have expired in major markets.

The most relevant protection categories for a new ceftazidime product would be:

1. Specific ceftazidime salt, hydrate, or crystalline forms.
2. Dry-powder manufacturing processes.
3. Sodium carbonate concentration ranges.
4. Stabilized liquid compositions.
5. Ready-to-use infusion bags.
6. Extended refrigerated or room-temperature stability.
7. Container-closure systems.
8. Premixed or dual-chamber delivery systems.
9. Specific methods of treating infections or dosing populations.

A generic ceftazidime injection generally relies on abbreviated regulatory pathways rather than new-drug exclusivity. A new formulation may obtain limited patent protection for a delivery system or stability profile, but that protection would not recreate broad exclusivity over ceftazidime.

Orange Book status

The Orange Book's relevance is limited for an older ceftazidime injectable product. FDA Orange Book listings focus on approved drug products, therapeutic equivalence, patents, and regulatory exclusivity. Any listed patent must be assessed by product, NDA, dosage form, and patent-use code rather than by the active ingredient alone (FDA, n.d.-b).

For ceftazidime injection, the practical competitive barrier is generally abbreviated approval, manufacturing capability, sterile supply, and hospital contracting. It is not a live compound patent barrier.

Patent expiration and Paragraph IV risk

The original ceftazidime patent rights expired before the current generic market developed. A generic entrant would not normally face a meaningful Paragraph IV challenge against the original ceftazidime molecule.

Paragraph IV risk could arise if a new branded product claims:

• A proprietary liquid formulation.
• A defined stability period.
• A specialized container.
• A fixed-dose combination.
• A new dosing regimen.
• A formulation that materially reduces preparation time.

Those patents would be narrower than a compound patent and could be challenged through Paragraph IV certification if listed in the Orange Book against the relevant reference product.

When does Tazicef lose exclusivity?

Tazicef has no commercially relevant remaining exclusivity over ceftazidime in the United States. The molecule has long been available through generic manufacturers. Any remaining brand value relates to prescribing familiarity, institutional contracts, product availability, and quality history.

Exclusivity category	Tazicef position
Compound patent	Expired
Basic injectable formulation	Expired or commercially non-blocking
Regulatory exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orphan exclusivity	Not applicable to the general product
Orange Book patent barrier	No broad current barrier identified
Generic substitution	Established market pathway

Tazicef should therefore be evaluated as a mature injectable asset, not as a protected innovator product.

What formulation opportunities exist for Tazicef?

Ready-to-use infusion bags

A ready-to-use ceftazidime infusion could eliminate bedside reconstitution. The main benefits are:

• Fewer preparation steps.
• Lower pharmacy labor.
• Reduced handling risk.
• Better dose standardization.
• Faster emergency administration.
• Lower risk of reconstitution errors.

The main technical barrier is liquid stability. Ceftazidime is more difficult to commercialize as a long-shelf-life aqueous product than as a dry powder. Development must establish potency, degradation products, pH, visible and subvisible particles, container compatibility, and sterility throughout the proposed shelf life.

A frozen or refrigerated bag may be more feasible than a room-temperature product, but cold-chain requirements reduce the commercial advantage.

Dual-chamber systems

A dual-chamber vial or bag separates dry ceftazidime from the diluent until administration. This approach can preserve the stability advantages of a powder while delivering the convenience of a ready-to-use system.

Potential advantages include:

• Reduced reconstitution time.
• Longer shelf life than a fully liquid product.
• Lower risk of incorrect diluent selection.
• More controlled final concentration.

The disadvantages include higher packaging cost, device validation, more complex manufacturing, and potential device-related regulatory review.

Higher-concentration presentations

A concentrated presentation could reduce infusion volume and support fluid-restricted patients. The formulation must maintain acceptable solubility and injection tolerability. Increasing ceftazidime concentration can create precipitation, pH, osmolality, and administration-rate challenges.

Pediatric and neonatal presentations

A preservative-free, low-volume, clearly labeled presentation could target neonatal intensive care and pediatric hospitals. This opportunity depends on dose flexibility, withdrawal accuracy, low extractables and leachables, and compatibility with small-volume syringes.

A smaller vial or premeasured presentation could reduce waste from partially used vials. It would also require a commercial balance between unit price and reduced discard.

Extended in-use stability

Hospitals increasingly value products that remain stable after reconstitution or dilution. A product that supports a longer pharmacy-batched or refrigerated in-use period could reduce waste and improve workflow.

This claim must be supported by studies covering:

• Reconstituted vial stability.
• Diluted infusion stability.
• Storage temperature.
• Light exposure.
• Container type.
• Concentration range.
• Microbiological hold time.
• Chemical degradation.
• Particulate matter.

An extended in-use claim is potentially protectable if linked to a defined composition, container, concentration, and storage condition.

How does Tazicef compare with ceftazidime-avibactam?

Ceftazidime-avibactam, marketed in the United States as Avycaz, is a separate product with a different commercial and patent profile. It combines ceftazidime with avibactam, a beta-lactamase inhibitor, and targets resistant Gram-negative infections that may not be adequately treated with ceftazidime alone.

Factor	Tazicef	Ceftazidime-avibactam
Active ingredients	Ceftazidime	Ceftazidime plus avibactam
Market position	Mature generic antibiotic	Branded resistant-infection product
Excipient complexity	Low	More complex fixed-combination formulation
Compound exclusivity	Expired	Newer product with active patent and regulatory considerations
Price level	Low to moderate	High
Main differentiation	Supply and preparation efficiency	Resistance coverage and clinical positioning
Biosimilar risk	Not applicable	Not a biologic; generic or hybrid competition is relevant
Formulation opportunity	Premix, dual chamber, stability	Combination stability and delivery system

A Tazicef reformulation should not imply equivalence to ceftazidime-avibactam. The products address different clinical and commercial segments.

What generic launch risks exist for a Tazicef reformulation?

A new ceftazidime product faces several generic-entry scenarios.

Conventional vial launch

A conventional sterile powder vial is the easiest market entry route. It has the lowest development complexity but also the weakest differentiation. Competition is likely to focus on price, availability, manufacturing reliability, and contract terms.

Premixed liquid launch

A premixed bag may generate stronger hospital value but carries higher technical and regulatory risk. Generic manufacturers could attempt to develop equivalent or similar presentations after market entry, particularly if the commercial opportunity supports high-volume hospital contracting.

Device-enabled launch

A dual-chamber or ready-to-use device may generate a stronger intellectual-property position. It also increases manufacturing costs and creates device failure modes, including incomplete mixing, leakage, seal integrity failures, and activation problems.

Contracting risk

Hospitals and group purchasing organizations may prioritize low acquisition cost over preparation convenience unless the product demonstrates measurable savings. The business case must quantify:

• Pharmacy labor saved per dose.
• Reduction in discarded doses.
• Reduced preparation errors.
• Faster administration.
• Lower inventory burden.
• Reduced need for sterile compounding.

Which companies are challenging or competing with Tazicef?

The market is primarily supplied by generic injectable manufacturers rather than by companies challenging a live Tazicef patent. Competition can include:

• Generic ceftazidime vial suppliers.
• Contract manufacturers specializing in sterile powders.
• Hospital-premix manufacturers.
• Specialty injectable companies with pharmacy workflow products.
• Suppliers of ceftazidime-avibactam for resistant infections.

The competitive advantage is likely to come from manufacturing redundancy, fill-finish capacity, validated sterile processes, and reliable supply during antibiotic shortages. A company with only a low-price vial strategy may have limited pricing power.

What FDA regulatory pathway applies to a new Tazicef product?

A conventional ceftazidime injection can generally pursue an abbreviated new drug application if it meets the applicable reference-product and bioequivalence requirements. A materially different formulation, delivery system, or clinical use may require a 505(b)(2) application rather than a standard ANDA.

The regulatory classification depends on the proposed product:

Product concept	Likely regulatory issue
Same sterile powder and vial	ANDA-style generic pathway
Different excipient composition	Equivalence and safety assessment
Ready-to-use liquid	New stability and comparative requirements
Dual-chamber device	Drug-device combination review
New infection indication	Clinical and labeling support
Ceftazidime-avibactam combination	Separate combination-product pathway
Extended stability claim	Full stability and in-use data package

The key CMC risks are sterility assurance, potency, degradation products, reconstitution performance, container closure, and compatibility with infusion materials.

What manufacturing and IP barriers affect commercial entry?

Ceftazidime injection has low active-ingredient patent barriers but meaningful operational barriers.

Manufacturing barriers

• Sterile powder filling capability.
• Control of endotoxins and bioburden.
• Consistent particle and cake characteristics.
• Moisture control.
• Vial and stopper compatibility.
• Validated reconstitution performance.
• Reliable supply of sterile containers.
• Capacity for short-notice hospital demand.

Intellectual-property barriers

Potentially defensible claims could cover:

• A defined ceftazidime-sodium carbonate ratio.
• Moisture-controlled powder processing.
• A specific crystalline or hydrate state.
• A liquid formulation with improved stability.
• A dual-chamber package.
• An extended in-use stability profile.
• A specific container material or closure.
• A low-waste pediatric dosing system.

The strongest patent strategy would combine composition claims with manufacturing and packaging claims. A formulation patent alone may be vulnerable if competitors can achieve the same clinical and handling benefit through a different excipient system.

What licensing opportunities exist for Tazicef?

No major licensing opportunity is inherent in the legacy Tazicef brand itself. Commercial licensing could arise around:

• Proprietary premix technology.
• Dual-chamber packaging.
• Freeze-dried injectable processing.
• Sterile fill-finish capacity.
• Hospital pharmacy automation.
• Extended-stability liquid formulations.
• Regional distribution rights.
• Combination products for resistant Gram-negative infections.

A licensee would likely value manufacturing or delivery technology more than the Tazicef trademark. Regional rights may be relevant in markets with limited sterile injectable capacity or recurring antibiotic shortages.

How strong is the patent estate for Tazicef?

The legacy patent estate is weak for exclusivity purposes because the molecule and basic injectable product are mature. A new commercial program can still build a moderate, narrow estate around formulation and delivery.

Patent category	Strategic strength
Ceftazidime molecule	Very weak or expired
Basic dry-powder vial	Weak
Sodium carbonate formulation	Low to moderate, depending on claim specificity
Ready-to-use liquid	Moderate if stability is unexpected and reproducible
Dual-chamber delivery	Moderate to strong if device claims are well designed
Extended in-use stability	Moderate, subject to enablement and prior art
Pediatric low-waste system	Moderate
Manufacturing process	Moderate if difficult to design around
Hospital workflow integration	Limited pharmaceutical patent value

Key Takeaways

• Tazicef is a legacy ceftazidime injectable product with no meaningful broad exclusivity over the active ingredient.
• Sodium carbonate is the central formulation excipient and supports solubility and pH control.
• The best commercial opportunities are ready-to-use bags, dual-chamber systems, pediatric presentations, and extended in-use stability.
• A conventional generic vial is easy to enter but difficult to differentiate.
• Liquid and device-enabled products offer stronger commercial value but carry higher stability, packaging, and regulatory risk.
• Patent protection is most credible around formulation, container, device, process, and stability claims.
• Ceftazidime-avibactam is a separate product and should not be treated as a direct formulation equivalent to Tazicef.
• The principal business risks are sterile manufacturing capacity, hospital contracting, supply reliability, and the ability to prove measurable workflow savings.

Frequently Asked Questions

Is Tazicef still a patented drug?

No broad, commercially meaningful patent protection remains over ceftazidime itself. Any relevant protection for a new product would likely concern formulation, packaging, manufacturing, or delivery technology.

What is the main excipient in Tazicef?

Sodium carbonate is the principal formulation excipient in ceftazidime powder for injection. It supports an alkaline formulation environment and helps maintain solubility after reconstitution.

Can ceftazidime be sold as a premixed infusion?

Yes, but a premixed liquid requires extensive stability, sterility, compatibility, and container-closure development. A dual-chamber system may provide a more practical alternative to a fully liquid product.

Is Tazicef interchangeable with Avycaz?

No. Tazicef contains ceftazidime alone. Avycaz contains ceftazidime and avibactam and has a different spectrum, regulatory profile, clinical positioning, and commercial price.

What is the most attractive commercial reformulation of Tazicef?

A preservative-free, ready-to-use or dual-chamber presentation with validated extended in-use stability is the strongest opportunity. Its value depends on reducing pharmacy preparation time, waste, and dosing errors enough to justify a price premium.

References

1. U.S. Food and Drug Administration. (n.d.-a). Ceftazidime for injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.-c). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. U.S. Food and Drug Administration. (n.d.-d). Avycaz prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP Convention.